Alnylam to Webcast TTR Investor Day
Alnylam Pharmaceuticals (Nasdaq: ALNY) has announced plans to webcast its TTR Investor Day event on October 9, 2024, at 8:30 am ET. The event will be accessible through the Investors section of the company's website, with a replay available within 48 hours.
The TTR Investor Day will feature presentations from Alnylam's management team, including senior commercial leaders who will discuss launch preparation and market leadership potential in ATTR amyloidosis with cardiomyopathy (ATTR-CM). Dr. Ahmad Masri, Associate Professor of Medicine at Oregon Health & Science University, will join as a leading expert in ATTR amyloidosis to share insights on clinical management of ATTR-CM and unmet medical needs.
Alnylam Pharmaceuticals (Nasdaq: ALNY) ha annunciato piani per trasmettere in diretta il suo evento TTR Investor Day il 9 ottobre 2024, alle 8:30 ora dell'Est. L'evento sarà accessibile attraverso la sezione Investitori del sito web dell'azienda, con una registrazione disponibile entro 48 ore.
Il TTR Investor Day presenterà interventi del team di gestione di Alnylam, inclusi i dirigenti senior commerciali che discuteranno la preparazione al lancio e il potenziale di leadership di mercato nell'amelioidosi ATTR con cardiomiopatia (ATTR-CM). Il Dr. Ahmad Masri, Professore Associato di Medicina presso l'Oregon Health & Science University, parteciperà come esperto leader nell'amelioidosi ATTR per condividere informazioni sulla gestione clinica dell'ATTR-CM e dei bisogni medici insoddisfatti.
Alnylam Pharmaceuticals (Nasdaq: ALNY) ha anunciado planes para transmitir en vivo su evento TTR Investor Day el 9 de octubre de 2024, a las 8:30 am ET. El evento será accesible a través de la sección de Inversores del sitio web de la compañía, con una repetición disponible dentro de las 48 horas.
El TTR Investor Day contará con presentaciones del equipo directivo de Alnylam, incluidos líderes comerciales senior que discutirán la preparación para el lanzamiento y el potencial de liderazgo en el mercado en la amiloidosis ATTR con cardiomiopatía (ATTR-CM). El Dr. Ahmad Masri, Profesor Asociado de Medicina en la Universidad de Salud y Ciencia de Oregón, se unirá como experto destacado en amiloidosis ATTR para compartir ideas sobre la gestión clínica de ATTR-CM y las necesidades médicas no satisfechas.
알닐람 제약(나스닥: ALNY)이 2024년 10월 9일 오전 8시 30분(동부 표준시)에 TTR 투자자 데이 이벤트를 웹캐스트할 계획을 발표했습니다. 이 이벤트는 회사 웹사이트의 투자자 섹션을 통해 접근할 수 있으며, 48시간 이내에 다시 볼 수 있습니다.
TTR 투자자 데이에서는 알닐람의 경영진, 특히 ATTR 심근병증(ATTR-CM)에 대한 출시 준비 및 시장 리더십 잠재력을 논의할 수석 상업 리더들의 발표가 있을 예정입니다. 오레곤 건강과학대학교의 의과대학 부교수인 아흐마드 마스리 박사가 ATTR 아밀로이드증의 주요 전문가로 참여하여 ATTR-CM의 임상 관리 및 충족되지 않은 의료 필요성에 대한 통찰력을 공유할 것입니다.
Alnylam Pharmaceuticals (Nasdaq: ALNY) a annoncé des plans pour diffuser en direct son événement TTR Investor Day le 9 octobre 2024, à 8h30 HE. L'événement sera accessible via la section Investisseurs du site web de l'entreprise, avec une rediffusion disponible dans les 48 heures.
Le TTR Investor Day présentera des présentations de l'équipe de direction d'Alnylam, y compris des dirigeants commerciaux seniors qui discuteront de la préparation au lancement et du potentiel de leadership sur le marché dans l'amyloïdose ATTR avec cardiomyopathie (ATTR-CM). Dr. Ahmad Masri, professeur associé de médecine à l'Université de la santé et des sciences de l'Oregon, participera en tant qu'expert reconnu de l'amyloïdose ATTR pour partager des idées sur la gestion clinique de l'ATTR-CM et les besoins médicaux non satisfaits.
Alnylam Pharmaceuticals (Nasdaq: ALNY) hat Pläne angekündigt, am 9. Oktober 2024 um 8:30 Uhr ET seine TTR Investor Day-Veranstaltung per Webcast zu übertragen. Die Veranstaltung wird über den Investorenbereich der Unternehmenswebsite zugänglich sein, mit einem Wiederholungsangebot innerhalb von 48 Stunden.
Der TTR Investor Day wird Präsentationen des Managementteams von Alnylam umfassen, einschließlich leitender kommerzieller Führungskräfte, die über die Vorbereitung zur Markteinführung und das Marktführerschaftspotenzial bei ATTR-Amyloidose mit Kardiomyopathie (ATTR-CM) sprechen werden. Dr. Ahmad Masri, außerordentlicher Professor für Medizin an der Oregon Health & Science University, wird als führender Experte für ATTR-Amyloidose teilnehmen, um Einblicke in die klinische Betreuung von ATTR-CM und unerfüllte medizinische Bedürfnisse zu geben.
- None.
- None.
The TTR Investor Day will feature presentations from Alnylam’s management team, including senior leaders from the commercial organization who will discuss launch preparation and highlight the potential for market leadership in ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Alnylam will also be joined by a leading expert in ATTR amyloidosis, Dr. Ahmad Masri, M.D., M.S., Associate Professor of Medicine, Division of Cardiovascular Medicine, Oregon Health & Science University, who will share perspectives on the clinical management of ATTR-CM and unmet medical needs.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240926873155/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Josh Brodsky
(Investors)
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
FAQ
When is Alnylam's (ALNY) TTR Investor Day scheduled for 2024?
What will be discussed during Alnylam's (ALNY) TTR Investor Day?
Who is the external expert speaking at Alnylam's (ALNY) TTR Investor Day?
How can investors access Alnylam's (ALNY) TTR Investor Day webcast?
Will there be a replay of Alnylam's (ALNY) TTR Investor Day available?
